AtaiBeckley is a clinical-stage biopharmaceutical company focused on developing rapid-acting mental health therapies, including psychedelic-based neuroplastogens. The company was formed through the successful 2025 strategic combination of atai Life Sciences and Beckley Psytech. It trades on Nasdaq under ATAI.
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
